P38 MAP kinase inhibitor prevents diastolic dysfunction in rats following HIV gp120 injection in vivo

Cardiovascular Toxicology

Volumn 9, Issue 3, 2009, Pages 142-150

  Berzingi, Chalak ^a   Chen, Fangping ^a   Finkel, Mitchell S ^a,b,c  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Adrenergic signaling; Cardiomyopathy; Gp120; Lusitropy; P38 MAP kinase

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; ISOPRENALINE; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; RECOMBINANT GLYCOPROTEIN GP 120; TROPONIN I; GLYCOPROTEIN GP 120; IMIDAZOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE;

ADRENERGIC STIMULATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DIASTOLIC DYSFUNCTION; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG MECHANISM; ENZYME INHIBITION; HEART HEMODYNAMICS; HEART INFARCTION PREVENTION; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; RAT; ANIMAL; CARDIOMYOPATHY; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DIASTOLIC HEART FAILURE; DRUG ANTAGONISM; ENZYMOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

RATTUS;

ANIMALS; CARDIOMYOPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART FAILURE, DIASTOLIC; HIV ENVELOPE PROTEIN GP120; IMIDAZOLES; MALE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 77950945010     PISSN: 15307905     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12012-009-9047-1     Document Type: Article

References (36)

1. Calasbrese, L. H., Proffitt, M. R., Yen-Lieberman, B., Hobbs, R. E., & Ratliff, N. B. (1987). Congestive cardiomyopathy and illness related to the acquired immunodeficiency syndrome (AIDS) associated with isolation of retrovirus from myocardium. Annals of Internal Medicine, 107, 691-692.
2. Stewart, J. M., Kaul, A., Gromisch, D. S., Reyes, E., Woolf, P. K., & Gowitz, M. H. (1989). Symptomatic cardiac dysfunction in children with human immunodeficiency virus infection. American Heart Journal, 117, 140-144.
3. Mirri, A., Rapezzi, C., Iacopi, F., Ortolani, P., Binetti, G., Fabbri, M., et al. (1990). Cardiac involvement in HIV infection: A prospective, multicenter clinical and echocardiographic study. Cardiologia, 35, 203-209.
4. Coudray, N., de Zuttere, D., Force, G., Champetier de Ribes, D., Pourny, J. C., Antony, I., et al. (1995). Left ventricular diastolic function in asymptomatic and symptomatic human immunodeficiency virus carriers: An echocardiographic study. European Heart Journal, 16, 61-67.
5. Barbaro, G., Barbarini, G., & Di Lorenzo, G. (1996). Early impairment of systolic and diastolic function in asymptomatic HIV-positive patients: A multicenter echocardiographic and echo-Doppler study. The Gruppo Italiano Per lo Studio Cardiologico dei Pazienti Affetti da AIDS. AIDS Research and Human Retroviruses, 12, 1559-1563.
6. Cardoso, J. S., Moura, B., Martins, L., Mota-Miranda, A., Rocha Gonçalves, F., & Lecour, H. (1998). Left ventricular dysfunction in human immunodeficiency virus (HIV)-infected patients. International Journal of Cardiology, 63, 37-45 (Pubitemid 28060224)
7. Barbaro, G., & Lipshultz, S. E. (2001). Pathogenesis of HIVassociated cardiomyopathy. Annals of the New York Academy of Sciences, 946, 57-81.
8. Monsuez, J. J., Escaut, L., Teicher, E., et al. (2007). Cytokines in HIV-associated cardiomyopathy. International Journal of Cardiology, 120, 150-157.
9. Currie, P. F., Goldman, J. H., Caforio, A. L., et al. (1998). Cardiac autoimmunity in HIV related heart muscle disease. Heart, 79, 599-604.
10. Buonaguro, L., Barillari, G., Chang, H. K., et al. (1992). Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokines. Journal of Virology, 66, 7159-7167.
11. Rerkpattanapipat, P., Wongpraparut, N., & Larry, E. (2000). Cardiac manifestations of acquired immunodeficiency syndrome. Archives of Internal Medicine, 160, 602-608.
12. Kan, H., Xie, Z., & Finkel, M. S. (2000). HIV gp120 enhances NO production by cardiac myocytes through p38 MAP kinasemediated NF-jB activation. American Journal of Physiology, 279, H3138-H3143.
13. Kan, H., Xie, Z., & Finkel, M. S. (2004). P38 MAP kinase mediated negative inotropic effect of HIV gp120 on cardiac myocytes. American Journal of Physiology. Cell Physiology, 286, C1-C7.
14. Kan, H., Xie, Z., & Finkel, M. S. (2006). IPLA2 inhibitor blocks negative inotropic effect of HIV gp120 on cardiac myocytes. Journal of Molecular and Cellular Cardiology, 40, 131-137.
15. Yuan, Y., Kan, H., Fang, Q., Chen, F., & Finkel, M. S. (2008). CXCR4 receptor antagonist blocks cardiac myocyte P38 MAP kinase phosphorylation by HIV gp120. Cardiovascular Toxicology, 8, 173-180.
16. Chen, F., Shannon, K., Ding, S., Silva, M. E., Wetzel, G. T., Klitzner, T. S., et al. (2002). HIV type 1 glycoprotein 120 inhibits cardiac myocyte contraction. AIDS Research and Human Retroviruses, 18, 777-784.
17. Raidel, S. M., Haase, C., Jansen, N. R., et al. (2002). Targeted myocardial transgenic expression of HIV Tat causes cardiomyopathy and mitochondrial damage. American Journal of Physiology. Heart and Circulatory Physiology, 282, H1672-H1678.
18. Klasse, P. J., & Moore, J. P. (2008). Is there enough gp120 in the body fluids of HIV-1-infected individuals to have biologically significant effects? Virology, 323, 1-8.
19. Oh, S. K., Cruikshank, W. W., Raina, J., Blanchard, G. C., Adler, W. H., Walker, J., et al. (1992). Identification of HIV-1 envelope glycoprotein in the serum of AIDS and ARC patients. Journal of Acquired Immune Deficiency Syndromes, 5, 251-256.
20. Gilbert, M., Kirihara, J., & Mills, J. (1991). Enzyme-linked immunoassay for human immunodeficiency virus type 1 envelope glycoprotein 120. Journal of Clinical Microbiology, 29, 142-147.
21. Khanna, D., Kan, H., Fang, Q., Xie, Z., Underwood, B. L., Jain, A. C., et al. (2007). Inducible nitric oxide synthase attenuates adrenergic signaling in alcohol fed rats. Journal of Cardiovascular Pharmacology, 50, 692-696.
22. Wang, Q., Brunner, H. R., & Burnier, M. (2004). Determination of cardiac contractility in awake unsedated mice with a fluidfilled catheter. American Journal of Physiology. Heart and Crculatory Physiology, 286, H806-H814.
23. Lee, H. B., & Blaufox, M. D. (1985). Blood volume in the rat. Journal of Nuclear Medicine, 25, 72-76.
24. To, L. P., Balkasubramanian, V., Charlton, M. E., Francis, T. A., Doyle, C., & Sweetnam, P. M. (1992). Development and characterization of a whole-cell radioligand assay for [125I] gp120 of HIV-1. Journal of Immunoassay, 13, 61-83.
25. Liggett, S. B. (2001). b-Adrenergic receptors in the failing heart: The good, the bad, and the unknown. Journal of Clinical Investigation, 107, 947-948.
26. Liu, Q., & Hofmann, P. A. (2003). Modulation of protein phosphatase 2a by adenosine A1 receptors in cardiomyocytes: Role for p38 MAPK. American Journal of Physiology. Heart and Circulatory Physiology, 285, H97-H103.
27. Itoh, S., Ding, B., Bains, C. P., Wang, N., Takeishi, Y., Jalili, T., et al. (2005). Role of p90 ribosomal S6 kinase (p90RSK) in reactive oxygen species and protein kinase C beta (PKC-beta)-mediated cardiac troponin I phosphorylation. Journal of Biological Chemistry, 280, 24135-24142.
28. Sakthivel, S., Finley, N. L., Rosevear, P. R., Lorenz, J. N., Gulick, J., Kim, S., et al. (2005). In vivo and in vitro analysis of cardiac troponin I phosphorylation. Journal of Biological Chemistry, 280, 703-714.
29. Schowoerer, A. P., Neuber, C., Schmechel, A., Melnychenko, I., Mearini, G., Boknik, P., et al. (2008). Mechanical unloading of the rat heart involves marked changes in the protein kinase-phosphatase balance. Journal of Molecular and Cellular Cardiology, 45, 846-852.
30. Fisher, S. D., Easley, K. A., Orav, E. J., Colan, S. D., Starc, T. J., Bricker, J. T., et al. (2005). Pediatric pulmonary and cardiovascular complications of vertically transmitted HIV infection (P2C2) study group. Mild dilated cardiomyopathy and increased left ventricular mass predict mortality: The prospective P2C2 HIV Multicenter Study. American Heart Journal, 150, 439-447.
31. Twagirumukiza, M., Nkeramihigo, E., Seminega, B., Gasakure, E., Boccara, F., & Barbaro, G. (2007). Prevalence of dilated cardiomyopathy in HIV-infected African patients not receiving HAART: A multicenter, observational, prospective, cohort study in Rwanda. Current HIV Research, 5, 129-137.
32. Kristoffersen, U. S., Lebech, A. M., Gerstoft, J., Hesse, B., Petersen, C. L., Gutte, H., et al. (2008). Right and left cardiac function in HIV-infected patients investigated using radionuclide ventriculography and brain natriuretic peptide: A 5-year followup study. HIV Medicine, 9, 180-186.
33. Khunnawat, C., Mukerji, S., Havlichek, D., Jr., Touma, R., & Abela, G. S. (2008). Cardiovascular manifestations in human immunodeficiency virus-infected patients. American Journal of Cardiology, 102, 635-642.
34. El Hattaoui, M., Charei, N., Boumzebra, D., Aajly, L.,&Fadouach, S. (2008). Prevalence of cardiomyopathy in HIV infection: Prospective study on 158 HIV patients. Médecine et Maladies Infectieuses, 38, 387-391.
35. Otis, J. S., Ashikhmin, Y. I., Brown, L. S.,& Guidot, D. M. (2008). Effect of HIV-1-related protein expression on cardiac and skeletal muscles from transgenic rats. AIDS Research and Therapy, 5, 8.
36. Fiala, M., Popik, W., Qiao, J. H., et al. (2004). HIV-1 induces cardiomyopathy by cardiomyocyte invasion and gp120, Tat, and cytokine apoptotic signaling. Cardiovascular Toxicology, 4, 97-107